Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Operating Cash Flow

Cash generated by the company's core business operations during the period.

Haemonetics CorporationNYSE: HAE

Operating Cash Flow · Q1 FY2027 · quarter ended Jun 2026

Operating cash flow growth accelerates

Q1 FY2027 operating cash flow of $52.32M rose 200.8% year over year, ahead of the +44.9% change in trailing-twelve-month operating cash flow. Sequentially, it fell 26.2% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Operating cash flow amounted to 22.0% of revenue in FY2026, up 8.6 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +200.8% holds above the trailing-twelve-month pace of +44.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$52.32M-26.2% QoQ
Last fiscal yearMar 2026
$293.22M+61.4% YoY
LTMJun 2026
$328.15M+44.9% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+200.8%——
1 year+61.4%——
3-year CAGR+2.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2026
293.22M USD
Year-over-year change
+61.4%
4-year CAGR
+14.2%

Operating Cash Flow vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 operating cash flow of $328.15M is the 3rd largest of the 10 companies compared; the peer median is $205.44M.
  • Its year-over-year change of +44.9% is the 2nd highest of 10, against a peer median of -2.1%.
  • Operating cash flow amounts to 24.3% of revenue for HAE, versus a peer median of 14.0%.
HAE Competitors Peer median
Operating Cash Flow for HAE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$1.8B +19.7%—16.6%
BEAMBeam Therapeutics Inc.LTM Jun 2026$359.38M +4.2%—230.3%
HAEHaemonetics CorporationLTM Jun 2026$328.15M +44.9%+2.4%24.3%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$326.79M +28.4%+0.6%14.0%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$268M -39.5%-23.1%7.3%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$208.21M -22.3%+21.6%34.9%
ITGRInteger Holdings CorporationLTM Jul 2026$205.44M -2.1%+19.0%11.2%
WRBYWarby Parker Inc.LTM Jun 2026$95.36M -18.3%+120.2%10.5%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$87.31M +81.5%+47.4%34.1%
QDELQuidelOrtho CorporationLTM Mar 2026$6.6M -95.6%-50.8%0.2%
Peer median (excluding HAE) $205.44M-2.1%+19.0%14.0%

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income43.38M115.4M117.56M167.68M97.31M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
Deferred Income Tax5.01M4.78M(1.01M)(15.7M)(714K)
Stock-Based Compensation24.36M25.58M28.33M29.64M33.83M
Change in Working Capital(15.18M)25.5M(63.07M)(91.98M)(23.65M)
Accounts Receivables(34.97M)(24.42M)(24.19M)6.96M(14.88M)
Inventory24.31M30.75M(60.06M)(64.7M)47.36M
Accounts Payables039.82M00(16.57M)
Other Working Capital(4.51M)(20.65M)21.19M(34.24M)(39.56M)
Other Non-Cash Items16.95M8.48M2.73M(23.49M)74.74M
Operating Cash Flow172.26M273.06M181.75M181.73M293.22M
Capital Expenditures(96.51M)(110.19M)(38.13M)(39.28M)(32.78M)
Acquisitions (Net)8.14M(2M)(242.35M)(107.62M)1.38M
Purchases of Investments0(33.21M)000
Sales of Investments00000
Other Investing Activities2.02M1.61M(41.91M)(15M)(87.96M)
Investing Cash Flow(86.35M)(143.79M)(322.39M)(161.9M)(179.55M)
Debt Repayment(17.5M)(9.63M)37.75M447.31M(6.25M)
Common Stock Issued6.55M01.33M(1.91M)7.89M
Common Stock Repurchased0(75M)0(225M)(175M)
Dividends Paid00000
Other Financing Activities(4.8M)(15.74M)(922K)(111.58M)(5.1M)
Financing Cash Flow(15.75M)(100.36M)38.16M108.82M(178.46M)
Effect of Forex Changes(2.98M)(3.94M)(3.19M)(685K)3.46M
Net Change in Cash67.19M24.97M(105.67M)127.96M(61.32M)
Free Cash Flow75.75M162.87M143.63M142.45M260.44M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.